Patch testing to detect contact hypersensitivity to corticosteroids. by Akila, K
PATCH TESTING TO DETECT CONTACT 
HYPERSENSITIVITY TO CORTICOSTEROIDS 
 
Dissertation Submitted to 
 
 
THE TAMILNADU DR. M.G.R. MEDICAL UNIVERSITY 
 
In fulfilment of the regulations for the award of the degree 
 
 
M.D. 
 
DERMATOLOGY, VENEREOLOGY AND LEPROLOGY 
 
 
 
 
 
 
 
 
 
 
 
 
DEPARTMENT OF DERMATOLOGY, VENEROLOGY 
AND LEPROLOGY 
 
 
PSG INSTITUTE OF MEDICAL SCIENCE AND RESEARCH 
THE TAMILNADU DR.M.G.R.MEDICAL UNIVERSITY 
CHENNAI, TAMILNADU 
 
APRIL 2016 
 PATCH TESTING TO DETECT CONTACT 
HYPERSENSITIVITY TO CORTICOSTEROIDS 
 
In fulfilment of the regulations for the award of the degree 
 
M.D. 
 
DERMATOLOGY, VENEREOLOGY AND LEPROLOGY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GUIDE 
 
DR. C.R. SRINIVAS, MD 
DEPARTMENT OF DERMATOLOGY, 
VENEREOLOGY AND LEPROLOGY 
 
 
 
 
PSG INSTITUTE OF MEDICAL SCIENCE AND RESEARCH 
THE TAMILNADU DR.M.G.R.MEDICAL UNIVERSITY 
CHENNAI, TAMILNADU 
 
APRIL 2016 
  
 
CERTIFICATE 
 
 This is  certify  that the thesis  entitled “PATCH TESTING                   
TO DETECT CONTACT HYPERSENSITIVITY TO 
CORTICOSTEROIDS”  is a bonafide work of  DR. AKILA  K. done 
under the direct guidance and supervision of  DR. C.R. SRINIVAS,  MD, in 
the department of Dermatology, Venereology and Leprology, PSG Institute of 
Medical Sciences and Research, Coimbatore in fulfillment of the regulations of 
Dr.MGR Medical University for the award of MD degree in Dermatology, 
Venereology and Leprology. 
 
 
 
DR. C. R. SRINIVAS     DR.RAMALINGAM 
Professor & Head of Dept.                         DEAN 
Dept. of DVL 
 
 
 
 
 
 
 
 
  
DECLARATION 
 
 I hereby declare that this dissertation entitled “PATCH TESTING                   
TO DETECT CONTACT HYPERSENSITIVITY TO 
CORTICOSTEROIDS ”  was prepared by me under the direct guidance  
and supervision of  DR. C.R. SRINIVAS, MD,     PSG Institute of Medical 
Sciences and Research, Coimbatore. 
 
The dissertation is submitted to the Tamilnadu Dr.MGR Medical 
University in fulfillment of the University regulation for the award of MD 
degree in Dermatology, Venereology and Leprology.  This dissertation has not 
been submitted for the award of any other Degree or Diploma. 
 
 
 
DR. AKILA  K. 
 
 
 
 
 
 
  
CERTIFICATE BY THE GUIDE 
 
This is certify that the thesis entitled “PATCH TESTING                   
TO DETECT CONTACT HYPERSENSITIVITY TO 
CORTICOSTEROIDS” is a bonafide work of   DR. AKILA K. done under 
my direct guidance and supervision in the department of Dermatology, 
Venereology and Leprology, PSG Institute of Medical Sciences and Research, 
Coimbatore in fulfillment of the regulations of Dr.MGR Medical University for 
the award of MD degree in Dermatology, Venereology and Leprology. 
 
 
 
DR. C.R. SRINIVAS    
Professor       
Dept. of DVL       
 
ACKNOWLEDGEMENT 
 
 On the very outset, I express my sincere gratitude to Dr.C.R.Srinivas 
who had guided me from scratch till the last minute. I thank him for giving me 
this opportunity and kindling me to go into every detail involved in regard to 
this study “Patch testing to detect contact hypersensitivity to corticosteroids.” I 
thank him for being an example as to how every student reason out everything. 
I am grateful to Dr. Reena Rai who had constantly contemplated the progress 
of my post graduation and my dissertation and for all her driving force and 
knowledge she imparted on us. 
 
 I thank Dr. Surendran and Dr. Mahadevan for their enlightening 
thoughts towards clinical and therapeutics. 
 
 I express my thanks to Dr. Chemboli Lakshmi for her contributions. 
 
 I thank Dr. Shanmuga Sekar and Dr. Karthiga for their guidance 
regarding certain practical issues in respect to the study. 
 
 I also thank Dr.Sornakumar, Dr. Kumaresan, Dr.Pradeep, 
Dr.Kavitha,Dr.Deepak and Dr.Priya for their support in completion of my 
thesis. 
 
 I wish to express my gratitiudes towards my fellow juniors and seniors 
who contributed their time and efforts. 
 I thank all our staff including Mr.Thirumoorthy, technician and 
Mrs.Shanti for their endeavours. 
 
 I also place a sincere note of appreciation to the patients who 
contributed their efforts towards the success of this tedious study  
 
 I wholeheartedly thank my dear colleagues Dr.Manu Vidhya, Dr.Anita, 
Dr.Revathi for their constant support and co-operation throughout the study. 
I express all my love and gratitude towards my family – my father, mother, 
brother, sister in law, lovely daughter Sangamithra, cute little Kavya and last 
but never the least my husband for being by my side in all hardships and 
happiness throughout my postgraduation course and dissertation 
 
 TABLE OF CONTENTS 
 
1.  INTRODUCTION     1 
2.  AIMS AND OBJECTIVE    6 
3.  REVIEW OF LITERATURE   7-53 
4.  MATERIALS AND METHODS   54-57 
5.  RESULT      58-70 
6.  DISCUSSION     71-79 
7.  CONCLUSION     80 
8.  BIBLIOGRAPHY 
9.  ANNEXURES 
Clinical Photographs 
Consent Form 
Proforma 
Master Chart 
List of abbreviations  
 
 
LIST OF TABLES 
 
Table 
No Content 
Page  
No. 
1 PROCESSES INVOLVED IN ALLERGIC CONTACT 
DERMATITIS 
10 
2 ICDRG SCALE 20 
3 DERMATOLOGICAL INDICATIONS OF TOPICAL 
CORTICOSTEROIDS 
26 
4 MECHANISM OF ACTION OF TOPICAL 
CORTICOSTEROIDS  
27 
5 CLASSIFICATION BASED ON POTENCY 31 
6 SIDE EFFECTS OF TOPICAL CORTICOSTEROIDS 35 - 36 
7 VEHICLES USED COMMONLY AND THEIR 
ADVERSE EFFECTS 
38 
8 PECULIAR REACTIONS SEEN IN CORTICOSTEROID 
PATCH TEST 
45 
9 LIST OF ALLERGENS USED 51 
10 COMMONLY USED TOPICAL PREPARATIONS BY 
DERMATOLOGISTS IN OUR INSTITUTION 
52 
11 CORTICOSTEROID SERIES 56 
12 AGE SEX DISTRIBUTION 58 
13 DURATION OF COMPLAINTS FOR WHICH TOPICAL 
STEROID WAS APPLIED 
60 
14 PRIMARY DIAGNOSIS 62 
15 PAST TREATMENT DETAILS 64 
16 DETAILS OF TOPICALS 65 - 66 
17 PRESENTING COMPLAINTS 67 
18 FREQUENCY OF ALLERGEN POSITIVITY IN THE 
CORTICOSTEROID SERIES 
68 
 
LIST OF FIGURES 
 
No Content Page  No 
1. IMMUNOLOGICAL MECHANISM OF ALLERGIC CONTACT DERMATITIS 9 
2. ICDRG SCALE 20 
3. ANNEXIN FUNCTION 28 
4. CORTICOSTEROID EFFECTS 28 
5. FINGERTIP UNIT 34 
6. SITES IN CORTICOSTEROID MOLECULE THAT DETERMINES CROSS REACTIONS 49 
7. ILLUSTRATION OF GROUP SPECIFIC NOMENCLATURE 50 
8. AGE GROUP 59 
9. MALE FEMALE RATIO 59 
10. DURATION OF COMPLAINTS FOR WHICH TOPICAL STEROID WAS APPLIED 61 
11. PRIMARY DIAGNOSIS 63 
12. TOPICAL PREPARATIONS USED 64 
13 PRESENTING COMPLAINTS 67 
14 FREQUENCY OF ALLERGEN POSITIVITY IN THE CORTICOSTEROID SERIES  69 
15 PERCENTAGE OF ALLERGEN POSITIVITY  70 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
PATCH TESTING TO DETECT CONTACT HYPERSENSITIVITY TO 
CORTICOSTEROIDS 
Introduction: 
Topical corticosteroids are extensively used preparations as prescription medicines and as 
over the counter medications in a wide variety of inflammatory dermatosis. These are 
increasingly recognized as a cause of allergic contact dermatitis. The incidence of which 
is reported to be 0.5 – 5% in various studies in Europe and USA. Studies in South East 
Asia show a prevalence of 3.29% in Thailand. But there are limited data available in 
India and no studies determining the same. The subtle clinical presentations are 
responsible for missing this condition by the practicing doctors. One should thus consider 
this diagnosis when there is worsening or poor response of the existing dermatosis to 
topical steroids. 
Objectives: 
To study the contact hypersensitivity by patch testing in patients who do not respond to 
or aggravate after using topical corticosteroids. 
Materials and Methods:  
24 patients aged 14 to 82 years with 17 males and 7 females underwent corticosteroid 
patch testing with chemotechnique series which had 9 corticosteroid allergens including 
control – petrolatum and patients own products which they were applying recently. 
Reading was taken on Day3, 5 and 7 and results interpreted according to ICDRG scale. 
Results: 
 4 out of 24 patients (16.3% positivity) tested positive to the allergens in the 
corticosteroid series and 1 tested positive patients own medication.  
Conclusion: 
On reviewing the details of the positive outcomes- They were single positivity’s except in 
one patient with reaction of two different groups of steroids – tixocortol of Group A in 
the series and Flutivate ointment (Fluticasone) in her own medications. The other patterns 
that were observed were that the patients included in the study had longer duration of 
dermatosis, hence long term application of steroids. The primary diagnosis for which 
topical steroid most commonly used was Atopic dermatosis followed by stasis dermatitis 
and allergic contact dermatitis. Thus, patch testing in patients suspected with 
corticosteroid hypersensitivity will help in directing therapy. 
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INTRODUCTION 
 
Edward Kendall and Philip Hench first demonstrated the therapeutic 
properties of corticosteroids in 1948, which was then used in the treatment of 
rheumatoid arthritis.1 
 
 A drug that reduces proliferation and inflammation of the skin was then 
described by Sulzberger et al as hydrocortisone which is a naturally occurring 
glucocorticoid hormone in the year 1952. This hormone was then chemically 
modified which resulted in multiple corticosteroid molecules of varying strength, 
with multiple properties. 2 
 
Since it is very useful against an array of inflammatory skin pathologies 
and that it is commonly used by dermatologists many patients because of easy 
availability abuse it. Over the counter availability and presence of corticosteroids 
in various commercially available cosmetic products increases the chances of 
exposure of the same.3 
  
Corticosteroids inhibit the transcription of numerous pro-inflammatory 
cytokines/mediators. Apart from these factors contributing to their anti-
inflammatory and immunosuppressant properties the mechanism by which it 
inhibits the expression of adhesion molecule which are expressed in the surface of 
the endothelial cells in inflammation and causes apoptosis of basophils.4 
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 It can thus be explained that the corticosteroids which has potent anti-
inflammatory agents and immunomodulators used in the treatment of allergic 
manifestations (in the broad sense) are capable of producing contact sensitization 
is thus paradoxical.5 
 
 These contact hypersensitivity reactions were first described in the 1950’s, 
which was following topical and parenteral hydrocortisone.6 
 
 Allergic contact dermatitis is an inflammatory skin reaction to direct 
contact with any substance that a person is previously sensitized. It occurs in two 
phases.  
1. Sensitization phase – where immune system is primed to an allergen.  
2. Second – elicitation of the allergy - a Type IV delayed hypersensitivity 
reaction in which a cell-mediated allergic response is triggered.7 
 
 To develop contact hypersensitivity to any drug it requires prior exposure 
of the same to which antibodies are produced – either of the IgG or the IgE type 
and involves either CD4 or more commonly a CD8 type of T cell proliferation.8 
 
 As we discussed earlier there exists a huge array of corticosteroid 
molecules against innumerable indications and thus used both topical and 
parenteral. Although systemic sensitization is documented topical is by far the 
commonest.9 
3 
 
 
 Apart from these, intranasal and inhalations routes of sensitization are also 
noted.10  Understanding the properties of corticosteroids is also important to 
understand the mechanism of allergic contact dermatitis. This includes the various 
groups, their potencies, the preparation and vehicle on dispensing the drug. 
 
 The corticosteroid potency is classified upon the vasoconstrictive properties 
from mild to high potent ones, which are used depending upon the severity and the 
nature of the disease.11 
 
 Cutaneous side effects of topical corticosteroidsinclude skin atrophy – 
epidermis and dermis- resulting in hypopigmentation, acne, telengiectsia, striae 
etc. These thus limit the long term application. Apart from this because of the 
atrophy especially in intertriginous areas, face- it increases the penetration of 
allergens. 
  
 Sensitization to topical steroids are increasingly documented in association 
with those diseases which demands long term applications- most commonly noted 
in atopic dermatitis, stasis dermatitis, hand and foot eczema etc., It could also be 
explained by the fact that in these conditions due to impaired skin barrier functions 
there is enhanced penetration of the allergens. Also, the local pro-inflammatory 
(thus availability of Antigen presenting cell’s –LC’s) environment favours antigen 
presentation.8 
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The incidence of allergic contact dermatitis following topical application 
varies from 0.5 to 5%4,11-13 
 Only limited data are available of the prevalence and patterns of 
corticosteroid hypersensitivity in Asia. A study in Thailand estimated allergic 
contact dermatitis to corticosteroids to be 3.29%.110 
 In India no studies have been published regarding the same.3 
 
 The clinical features of contact hypersensitivity to corticosteroids are very 
subtle and hence easily missed.8 Any patient with chronic skin disease with topical 
steroid application has poor or no response, or worsening of symptoms on 
application of topical corticosteroids must thus be patch tested.13 
 
 Understanding the properties of corticosteroid molecules- its topical bio-
availability, the concentration and the vehicle that is optimal for patch testing is 
debatable. 
 
 Same is applicable regarding the readings – delayed reading should be 
advocated owing to its pharmacological- anti-inflammatory properties. Day 5 and 
Day 7 readings are thus recommened.7 
 
 Apart from the panel of allergen patients own medications has to be patch 
tested because it could only explain the factors present in the preparation that 
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might enhance the penetration-vehicles, excipients- preservatives, and package 
itself (nickel). 
 Interpretation of patch test results again is also peculiar in case of 
corticosteroids8 
• False positives and false negatives owing to its vasodilation and 
vasoconstriction properties.8 
• Edge effect in corticosteroids- thin rim of erythema because of the 
anti inflammatory effect at the site of patch testing and dilution of 
concentration in periphery has to be considered positive in case of 
corticosteroid patch testing.14 
 
NEED FOR STUDY 
 Hence our study was undertaken to determine the prevalence of contact 
hypersensitivity to topical corticosteroids among patients who had used it for a 
prolonged duration without significant improvement or among cases that 
worsened following the use of topical corticosteroid preparations. 
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AIM OF THE STUDY 
 
PRIMARY AIM 
• To study the contact hypersensitivity of patients to topical steroids who do 
not respond to or aggravate after using topical corticosteroids  
 
SECONDARY AIMS 
• To determine the prevalence in regard to the contact hypersensitivity to 
topical steroids in suspectedpts attending our OPD 
 
• To find and to recommend the use of suitable topical corticosteroid 
preparations devoid of the allergen and/or the allergen that may cross react  
 
 
 
 
 
 
 
 
7 
 
REVIEW OF LITERATURE 
 
 Skin being the outermost barrier of our body, is the first to encounter 
numerous substances from the environment, thus being exposed to various 
physical, chemical, and biological products that may give rise eczema.107 
 
Eczema (to boil) presents clinically as erythema, hyperpigmentation, scaling, 
vesicles with exudation.17 This can be  
1. Acute eczema- causing pink erythema and scaling with exudation. 
2. Subacute 
3. Chronic  - lichenification 
 
Eczema that is caused by exogenous agents which thus come in contact or 
penetrate the skin to produce inflammation is termed as contact eczema.15 
Allergic contact dermatitis is thus defined as an inflammatory skin 
reaction to direct contact with noxious agents present in the environment.16   
However, not all allergens are noxious.  
 
Contact dermatitis can be caused by  
 Irritant materials resulting in irritant contact dermatitis resulting from acids 
and alkalis.7or 
 Allergens resulting in allergic contact dermatitis.  
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Allergic contact dermatitis occurs as a specific immune response against 
the contactant to which the patient is previously sensitized. And the immune 
reaction, which is generated against the antigen, causes tissue damage. 17 
 
Allergic contact dermatitis/Contact hypersensitivity/contact sensitivity are 
all considered as synonymous terms.15 
 
 Contact hypersensitivity occurs as a result of  delayed hypersensitivity 
(DTH) reaction – which can be reproduced by direct contact of skin with the 
offending chemical in a person who is previously exposed to or sensitized to the 
same chemical.15 The site thus becomes erythematous, vesicular or scaly. 
 
 A succession of physicochemical processes occur that can be didactically 
divided into 2 phases all of which involves the immune system 
 
1)  Sensitization phase – In which, the immune system is primed to an allergen.  
2)  Elicitation of the allergy/challenge/efferent phase - a Type IV DTH in 
which, a cell-mediated allergic response is triggered.18 
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These are best understood with the help of this picture: 
  
 
Figure - 1 
 
The understanding of which is as follows:  
Three elements are required for a contact hypersensitivity reaction to take place 
which includes 
1. Antigen presenting cells or Langerhans/ dendritic cells (DC), 
2. Haptenspecific T-cells,  
3. Haptens.15 
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Table – 1 
PROCESSES INVOLVED IN ALLERGIC CONTACT DERMATITIS 
Haptens are of low molecular weight (<500 Daltons) which are nothing but 
the contact allergen that is responsible for causing allergic contact 
dermatitis. Not immunogenic on their own and need to bind to epidermal 
proteins.  
The physical and chemical properties of the haptens allow these to cross the 
stratum corneum106 
 
They form hapten-protein conjugates on coming in contact with the 
epidermis.  
Thus making it a complete antigen and hence protein reactive.  
This conjugate is a result of covalent binding to certain amino acids of 
protein carriers present in skin.  
The covalent binding is the result of interaction of nucleophilic–
electrophilic reactions between chemicals and some amino acids, such as 
cysteine 
 
These conjugates are recognized as a foreign body by the Langerhan cells 
or the dendritic cells (DCs), These then  internalizes the protein 
 
Langerhan cells are transported to the lymph nodes 
There they transform into dendritic cells by differentiation, which are 
immune – stimulatory in nature 
 
Enter the lymph glands and present the allergenic epitope associated with 
the allergen to the T lymphocytes.  
These processes are controlled by TNF-α and few IL-1, 13 and 18 which are 
cytokines and chemokines– that either promote or inhibit the mobilization 
and migration of these LCs. 
 
These T lymphocytes then clonally multiply after differentiation resulting in 
Memory T cells. 
Thus if  the same sensitized individual is exposed to the same allergen, these 
T lymphocytes will respond more quickly and aggressively, giving rise to 
the various manifestations of allergic contact dermatitis.18 
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Sensitisation phase lasts upto 10-15 days in man 
Elicitaion phase occurs as quickly as 24 hours.15 
 
 White et al. (1986) hypothesized that there is a threshold to this event of 
sensitization by allergens.   And depends upon the extent to which induces the up-
regulation of the required cytokines and inflammatory mediators.  
 
 The vehicle in which the allergen reaches the skin also determines the 
sensitisation of the epidermis by augumenting the percutaneous penetration hence 
influx of cytokines.18 
 
MEMORY RESPONSE 
 Upon sensitization to chemical that causes allergy, future contacts with the 
same substance can trigger a reaction, in the original site of sensitization – referred 
to as a memory response. Thus progressing directly to elicitation phase of allergic 
contact dermatitis.17 
 
 At the end of sensitization phase, memory T cells which have been 
activated the binding are found in theblood and in the skin (peripheral memory 
cells) and in the Lymph nodes- called as central. The skin though appears normal 
these memory T cells will be activated directly in the skin and excessively brought 
to the site if it comes in contact again.18 
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For example,  
 If a person has an allergic contact dermatitis due to nickel strap, touching 
the contact allergen present in coins, handles etc., can trigger an allergic reaction 
on the primary site. 
 
 This is a result of the memory T-lymphocytes, which remain in the skin of 
primary contact.  This Memory response, or “Retest Reactivity”, occurs in about 2 
to 3 days after contact, and can be present  for 2 to 4 weeks. 
 
 Thus in a person who is already sensitized with the same allergen the 
response is as early as 24 to 96 hours after contact with the causative allergen.(15-18) 
 
REGULATION OF CONTACT SENSITIVITY  
 
 Initially it was hypothesis that few days following hapten presentation there 
is down-regulation of the contact hypersensitivity due to removal of the allergen 
from the skin by body. 106 
 
 Although, there are reports that suggest that the allergens could say in the 
skin – epidermis for even more than 2 weeks after an application. There are 
reports where they have observed that ultraviolet radiation induced allergic contact 
dermatitis patients had persistence of ketoprofene in the skin for as long as years. 
13 
 
 
There are numerous mechanisms that involve in suppression of the 
regulatory mechanisms which are involved in the inflammation and hence limit 
tissue damage.  
Which include the following 102 
(i) the clearance of bound antigen by effector T lymphocytes 
(ii) recruitment of cytokines involves in the antagonizing action against 
inflammation  
(iii) binding of  non MHC ligands (likecadherins, PD-L1, RANK-L, etc.) for 
inhibitory immune receptors 
(iv) upregulation of T regulatory cells which down regulates these mechanisms.  
 
FUTURE PROSPECTIVES 
 
 Allergic contact dermatitis, is thus known to be mediated by T 
Lymphocytes of CD8 origin.  
There are ongoing studies that in molecular levels observe the binding of 
haptens, skin recruitment of CD8 T lymphocytes and the cellular networks 
involved in the same.17 
 Epicutaneous exposure to sensitizing chemicals activates thus recruits many 
inflammatory mediators and inflammatory pathways. 
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 Hence these are potential targets for detailed research and development of 
newer medications that attend to these mechanisms. Modalities that can somehow 
cause tolerance to these haptens in patients with contact sensitization are potential 
targets, but will need a detailed chemical and molecularstudies.18 
 
DIAGNOSIS OF ALLERGIC CONTACT DERMATITIS 
History 
Detailed history plays a crucial role in the diagnosis in regard to the 
duration, where and how it started and coincidence to any contact / topical 
applications.7 
 
Physical examination 
The distribution of dermatitis, in relation to the severity of the disease 
which usually correlates with the contact of the allergen. This is crucial for the 
diagnosis of allergic contact dermatitis.7   
Diagnostic studies for allergic contact dermatitis include the following: 
  1)  Patch testing 
 Pliny the younger noticed people developing itching when cutting pine tress 
in 1st century AD. Since then, patch testing and contact dermatitis go hand in hand. 
17,18,19 centuries- Pre Jaddhasson period researchers reproduced contact 
dermatitis by applying responsible agents onto intact skin.  
15 
 
In 1884, Neisserdemonstated the same in 8 cases of iodoform dermatitis 
and described regarding idiosyncrasy and then mercury associated reactions. 16 
 
 Jaddhason in 1895-1896 a who was a professor in Bressaleau university- 
department of dermatology in Germany had recorded numerous observations in 
regard to this field.  
 
 
 
 Patch test was first employed using blotting paper method 1847 by 
Staedler. An ophthalmologist named Collin in the year 1889, noted positive 
outcomes on application of  atropine patches to his patients who reported adverse 
outcomes on using atropine eye drops.19 
 
 However, Jadassohn has been rightly called the father of patch testing as he 
first scientifically established the role of patch testing in dermatitis 
medicamentosa.  He recogonised the process of delayed hypersensitivity to simple 
Joseph (Josef) Jadassohn 
September 10, 1863– March 24,1936 
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chemicals “gray mercury ointment applied on upper extensor arm covered by 
using a 5cm2 piece of white paper for 24 hours”, and called this patch test.16 
 
 The most important advance in the field of dermatology clinical practice in 
the twentieth century was by Sulzberger who highlighted the importance of proper 
standardization of patch testing to improve the outcome. 
 
 Bruno Bloch, Basel 1911 described technique of patch testing. Allergen is 
placed on a linear stip over the back and covered with a big pieces of guttapercha 
which is was held in place with zinc oxide adhesive plaster – size of patch – 1cm2. 
He also graded the skin reactions fom simple erythema to necrosis and 
ulceration.16 
 
 In the year 1931, Sulzberger and Wise had made a statement thatin the 
diagnosis of eczema and allergic contact dermatitis, patch testing should be used 
which is the single most effective tool in the diagnosis of allergic contact 
dermatitis.21 
 
In 1982 Colman stated that failure to use patch test wherever needed is and abuse. 
Fisher in the year 1986 said that a correctly applied and interpreted patch 
test is a scientific proof of allergic contact dermatitis. He also quoted that patch 
test is a complete bioassay as compared to the Henle Koch postulates – wherein a 
microorganism causing the disease must be isolated and should grow in pure 
17 
 
culture and produce the same clinical spectrum when inoculated in a healthy 
individual.Patch tests also are a purified etiologic agent that reproduces the clinical 
spectrum in a susceptible host. To achieve this, the following principles have to be 
used: 
1. The test should be performed with a known substance in a standard 
concentration  
2. The test must not be performed when the disease is acute 
3. The patient should be given proper instructions as to – leave the patch 
untouched for 48 hours unless if it burns severely wherein he can remove 
that alone care fully without disturbing others.  
4. The patient should also be instructed not to shower, engage in sports or 
heavy work 
5. Patch should be removed and read on the 2nd day – 48 hours and an 
additional reading at day5-7 (72-120 hours) using the key of North 
American contact dermatitis Group. 
6. Differentiating allergic from irritant seems to be difficult. Allergic reactions 
itch more intensely than irritant.7 
 
Patch testing is considered as the investigation of choice for detection of 
delayed hypersensitivity and as a gold standard investigation.19 
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 Thus epicutaneous test or the patch test is miniature form of allergic contact 
dermatitis by applying the suspected allergen and occluding an intact skin of 
patient with suspicion of contact dermatitis. The same principle of contact 
sensitivity where in the circulating memory T cells play a role in subsequent 
exposure is employed to produce a favourable outcome to treat the patient using 
concentrations that do no irritate the skin.20 
 
 Patch testing using multiple allergens also helps in impoved and accurate 
diagnosis. One has to keep in mind the exposure of the patient to all the suspected 
allergens in the patients environment.49 
 
 
 Concurrent medication with immunosuppresants should be avoided at the 
time of patch testing .Steroids can be used but not more than 15mg/day. To 
combat the itching antipruritics and antihistamines maybe used.  
 
Diagnosis by patch testing favours the patient in numerous ways – including 
 improvement of quality of life 
 cost effective investigation 
 cost of therapy is less.21 
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 Patch testing is done usually by the allergen panels available commercially 
– most commonly chemotechnique is used. These allergens are loaded in 
presterilisedfinn chamber (aluminium) with control – usually petrolatum. Secured 
with adhesive skin tapes.  
 
 Removed at 48 hours in broad daylight and read after half an hour which 
best detects the delayed response and an usual second reading is taken at 72 hours. 
Some substances although may require a late reading as described by Mark D.P 
Davis who observed that a delayed positive reaction was noted with palladium 
chloride,gold sodium thiosulfate, neomycin sulfate, dodecyl gallate, para-
phenylenediamine and for corticosteroids.20 
 
 Apart from this the patch test results are also influenced by the physico-
chemical properties – molecular and crystal size, lipophilicity of the molecule.19 
 
 We shall discuss later in regard to the patch testing in case of 
corticosteroids later. 
 
Interpretartion of patch test results 
 It is based on the ICDRG scale –Group ofInternational Contact Dermatitis 
Research The intensity of the reaction is scored and recorded on the days of patch 
test reading accordingly. Its crucial for a treating doctor to interpret the outcome.      
For example, irritant properties of cobalt chloride results in petechial response. 
20 
 
Which can easily mistaken for contact hypersensitivity 
For corticosteroids there is an edge effect due to dilution of allergen at the 
periphery and anti-inflammatory effect of the steroid in centre.21 
Table – 2 
ICDRG SCALE 
SYMBOL PRESENTATION INTERPRETATION 
- Nil reaction Negative 
? Erythema  
No infiltration 
Doubtful reaction 
 
+ Apart from erythema, there is infiltration, 
discrete papules 
Weak positive 
++ Apart from erythema, there is infiltration, 
discrete papules and few vesicles 
Strong positive 
+++ Apart from erythema, there is infiltration, 
discrete papules and confluent vesicles 
Extreme positive 
Ir Vesiculation, blitering and necrosis Irritant reaction 
Nt  Not tested 
 
 
Figure – 2   
ICDRG SCALE 
21 
 
 
 
2) Repeat open application test (ROAT) 
 
 It is particularly useful in patients who have a weak or mild (1+) type of 
reactions to a particular substance. It thus determines that the reaction is 
significant or not.74 
 
 ROAT is most useful when an individual has a 1+ reaction to a chemical 
found in a leave-on consumer product. 
 
 If a patient is 1+ allergic to a topical emollient, the patient is asked to apply 
the same twice a day behind the ear or neck and observed for reaction. If there is a 
positive response then the 1+ reaction is considered positive. If there is a negative 
response then the 1+ reaction can be discounted.21 
 
3) Dimethylgloxime Test 
 
 It is a chemical analysis wherein the material is tested if it contains a 
suspected allergen or not. It has been employed in patients suspected to have 
various allergies including- cobalt chloride, chromium, nickel, formaldehyde etc.,  
This test is used to detect nickel in metallic objects such as watch straps which 
would thus result in allergic contact dermatitis in sensitized patients.21 
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4) Intradermal testing 
 Intradermal testing is also used for the detection of allergic reactions to 
corticosteroids. This method may be of use in situations where inadequate 
percutaneous penetration of corticosteroids in patch testing may lead to false-
negative results.75,76 
 
Not all formulations are available for intradermal testing. 
 
 Intradermal testing is carried out by an intracutaneous injection of the test 
formulation with a 0.5 to 1.0 ml tuberculin syringe and 26- or 27-guage needle.  
 A volume of 0.1ml is injected into the superficial dermis of the flexor 
aspect of the forearm and a superficial bleb of 2 to 3 mm diameter should be 
obtained. 
  A 0.1ml intradermal injection of normal saline should be used as a control. 
Results should be read at 15 minutes, day 2, and day 4. A 5 to 10 mm wheal is 
considered to be a positive result. 21 
 
5) Skin Biopsy 
 Skin biopsy is rarely indicated in case of allergic contact dermatitis.  
 It is considered in difficult to diagnose conditions wherein the clinical 
picture mimics that of psoriasis, lymphoma. However it becomes a difficult task 
when areas involved are palms and soles which is not unusual. 
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 Histo-pathological examination of allergic contact dermatitis will reveal the 
following: 
 Epidermis may show hyperkeratosis, parakeratosis, acanthosisspongiosis 
and micro- vesicles 
 Dermis will have inflammatory infiltrate mainly comprised of lymphocytes 
and mononuclear cells 
 At times the picture may simulate mycosis fungoides which is espcecially 
well known in chronic actinic dermatitis which is a form of 
pohotodermatitis 
 
6) KOH Test 
 
 KOH test can be done to rule out fungal infections if any which appears to be 
a close differential in case of allergic contact dermatitis. 
 
 With all this background knowledge on allergic contact dermatitis, we are 
now discussing in detail about contact hypersensitivity to topical corticosteroids.75 
 
MANAGEMENT 
 
 The mainstay of therapy will be to address the etiologic factor – the 
causative allergen in case of allergic contact dermatitis. 
 
 Thus upon identification of the allergen, patient should be informed 
regarding the same and warned to identify and avoid the same. 
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 They should also be counseled regarding possible cross reacting substances. 
Emollients are used in almost all patients because of the associated scaling. In 
acute cases topical corticosteroids or at times wherein there is lots of edema and 
exudation at widespread areas even oral immunosuppresants may be indicated for 
a short period of time.103,104 
 
 Newer modalities of therapy include oral hyposensitisation and reducing 
the systemic load of the allergen. – commonly employed in nickel allergic contact 
dermatitis. By employing a diet devoid of nickel or counter act the effect using 
disulfuram.15 
 
TOPICAL CORTICOSTEROIDS 
 
 The novel drug in therapy of rheumatoid arthritis using a hormone – 
cortisone in 1950 fetched a Nobel prize award for Edward Kendall and Philip 
Hench along with a Switzerland based chemist Reichestein.1 
 
 Philip Showalter Hench  Edward Calvin Kendall     Tadeus Reichstein  
 
25 
 
 Topical corticosteroids are the mainstay of treatment of various 
dermatological disorders including atopic dermatitis, seborrheic dermatitis, contact 
dermatitis, lichen planus, insect bite reaction, psoriasis, etc., since the introduction 
of  “compound F” or hydrocortisone described in 1950, a natural glucocorticoid 
that reduces inflammation and proliferations in certain skin disorders.2  
 
 The mechanism by which it acts areimmunosuppressive, anti-inflammatory, 
anti-proliferative and vaso-constrictive properties of the corticosteroids. Structural 
and chemical changes in this lead to the discovery of various strength and 
properties of corticosteroid molecules. Hence multiple topical corticosteroid 
creams are available for use.8 
 
These effects of corticosteroids are owing to:24 
 The inhibition of various pro-inflammatory cytokines and transcription 
factors 
 basophils apoptosis 
 Expression of the adhesion molcules on the endothelial cells are reduced. 
 Inhibition of the capillary dilation, spongiosis, reduction of vascular 
permeability and lymphocyte function 
 Decrease the proliferation of  CD8 T lymphocytes7 
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Table - 3 
DERMATOLOGICAL INDICATIONS OF TOPICAL CORTICOSTEROIDS24,25 
 
GROUP OF DISORDER DERMATOSIS 
Dermatitis Seborreic dermatitis, Prurigonodularis, lichen simplex 
chronicus, atopic dermatitis, numular eczema, allergic 
contact dermatitis. 
Papulosquamous Psoriasis, lichen Planus 
Vesicobullous Vitiligo 
Autoimmune bullous pemphigoid, cictricialpemphigoid, pemphigus 
foliaceous 
Others lupus erythematosus, dermatomyosistis, morphea, 
alopecia areata, PUPP, early CTCL, Lichen sclerosis 
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Table - 4 
MECHANISM OF ACTION OF TOPICAL CORTICOSTEROIDS7,22 
Corticosteroid molecules penetrate though the membrane of the epidermis 
A steroid – receptor complex is formed by interaction with the various receptor 
proteins that are present in the cytoplasmat the cellular level by binds to the 
glucocorticoid receptor to form a corticosteroid-receptor complex which then 
translocates into the nucleus 
 
this then binds  to the glucocorticoid-responsive element of the target genes which 
changes the transcription of messenger RNA (mRNA).  
 
This mRNA thus transcribed acts as a template for synthesis of proteins that can 
have both agonistic or antagonistic effects  
Thus stimulating the production of a glycoprotein - lipocortin. Or annexin A1 
Annexin A1 is located in the basal keratinocytes cytolplasm of normal skin, 
whereas in the lesional skin it is translocated at the cell memberane 
 
The release of arachidonic acid from phospholipids by phospholipase A2 which 
will thus be inhibited by lipocortin 
 
This arachidonic acid is a basis for the formation of leukotrienes.  
Corticosteroids also inhibit mRNA responsible for interleukin-1 formation.  
 
These effects on interleukin-1 and arachidonic acid metabolism formation produce 
reduction in inflammation, immunomodulatory and anti-mitogenic effects. 
It also  inhibits  the transcription of various cytokines involved in atopic or contact 
dermatitis, such asIFNγ and TNFα 
The annexin 1 functions in various levels 
This juxtacrine interaction explains the mechanism by which anti-inflammatory 
process occurs.  
It upregulates  the glucocorticoid mediated leucocyte inhibition. 
Apart from this,  there is modulation of mast cells 
Antimitotic property – in psoriasis 
Apoptosis of eosinophils 
Vaso constrictive effects 
Immunosupressive is also by suppression of various immune mediators –DC’s, 
macrophages, endothelial cells and fibroblasts22 
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Figure -3  Annexin function 
 
 
 
 
Figure – 4 Corticosteroid Effects 
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 Key factors that should be considered to effectively use the therapeutic 
properties and decrease the side effects are25: 
 potency of the active agent 
 clinical efficacy of the selected agent, 
 vehicle,  
 affected  site, and  
 occlusive used or not.24 
 
 From hydrocortisone molecular modifications resulted in corticosteroids of 
varying potency. These include physiochemical alterations byhalogenation or 
esterification have produced more potent molecules.  
 
 Topical corticosteroids depending on their vaso-contrictive properties are 
classified from mild to high potent. However, it may not always correlate with the 
therapeutic efficacy.24 
 
SITE OF APPLICATION 
 The diseased site should be kept in mind while deciding upon the use of a 
particular corticosteroid molecule. As damaged epidermis may result in increased 
absorption.27   Soles of the feet or palms of the hand are areas with thick stratum 
comeum and allow very low penetration. Hence to achieve a good outcome 
clinically high potent preparations must be preferred.27 
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 Parts with thin stratum corneum, such as certain parts ofthe face.  
Eg.eyelids, scrotum, promote enhanced absorption. Hence are more prone for the 
adverse effects.  
 
 In patients with extensive areas  of dermatitis a medium to low potency 
steroid must be used to minimize the risk of systemic absorption and hence 
resulting in untoward effects. 
 
POTENCY 
 Depending on the vaso-constrictive properties classified into I-IV by 
Stoughton and Cornell in 1985.22 
 Reclassified by British National Formulary. Whereas the American systems 
classifies the corticosteroids into 7 
 Although knowledge of all this is needed each physician should know at 
least one drug in each class to treat various disorders efficiently with minimal side 
effects. 
 Weak steroids are preferred for highly responsive conditions. Eg: flexural 
psoriasis or atopic dermatitis,  
Potent steroids for recalcitrant or less responsive conditions. Eg. 
palmoplantar or nail psoriasis, lichen planus often require higher potency22 
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Table - 31 
CLASSIFICATION BASED ON POTENCY 
AMERICAN 
CLASSIFICATION2
3
 
BRITISH 
CLASSIFIC
ATION23 
REPRESENTATIVE MOLECULES23 
COMMON 
INDICATIONS23 
I 
Superpotent 
I Clobetasol propionate 0.05% 
cream/ointment 
Halobetasol propionate 0.05% 
cream/ointment 
Betamethasone dipropionate 0.05% 
ointment  
Alopecia areata 
Atopic dermatitis 
Discoid Lupus 
Hyperkeratotic 
eczema 
 
II 
Potent 
 
 
 
 
III 
Upper mid strength 
 
 
 
 
 
IV 
Mid strength 
II 
Potent 
Betamethasone dipropionate 0.05% 
cream 
Fluocinolone 0.05% ointment 
Halocinonide 0.1% cream 
Mometasonefuroate 0.1%ointment 
 
Betamethasone dipropionate 0.05% 
lotion 
Fluticasone propionate 0.005% 
ointment 
Triamcinolone acetonide 0.1% ointment 
Halometasone 0.05% cream 
 
Fluocinoloneacetoinide 0.025% 
ointment 
Mometasonefuroate 0.1% cream or 
lotion 
Lichen planus 
Lichen sclerosis 
Lichen simplex 
chrnoicus 
Nummular eczema 
 
Psoriasis 
Severe hand 
eczema 
 
 
 
 
Asteatotic eczema 
Atopic dermatitis 
V 
Lower mid strength 
 
 
 
 
 
 
VI 
Mild 
III 
Moderate 
Betamethasone valerate 0.1% cream 
Fluocinoloneacetonide 0.025% crema 
Fluticasone propionate 0.05% cream 
Hydrocortisone butyrate 0.1% cream 
 
 
 
 
Alcometasonedipropionate 0.05% 
cream or ointment 
Desonide 0.05% cream 
Fluocinoloneacetonide 0.01% cream 
Triamcinolone acetonide 0.025% cream 
Lichen sclerosis 
(vulva) 
Nummular eczema 
Seborrhoiec 
dermatitis 
Severe dermatitis 
Stasis dermatitis 
 
Dermatitis of 
intertrigo, perianal 
dermatitis 
VII 
Least potent 
IV  
Mild 
Hydrocortisone 1% /2.5% cream, lotion, 
ointment 
Dermatitis face 
Childern35 
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VEHICLE 
 
 Vehicle - functions as a carrier for the active drug and also hydrates the skin 
of the patient hence increasing the penetration of the corticosteroid. While 
selecting the corticosteroid the area of involvement and pattern of dermatitis. 
 
 Corticosteroid formulations available for topical use can be creams, 
ointments, lotions or sprays. 
 
 Ointments-consists usually of petrolatum which thus hydrates the epidermis 
by acting as a occlusive agent. It is ideal in patients with scaling and 
lichenification involving thick skin 
 
 Creams are cosmetically appealing and less greasy than ointments. It has a 
larger quantity of petrolatum. 
 
 Lotions have water base and hence do not have much of emollient effect. 
They are non-occlusive and ideal for application on hairy areas and flexures and 
for weeping lesions.24   
 
 According to Cornell and Stoughton, vehicle can directly modify the 
therapeutic as well as the side effects by changing the physicochemical properties 
of the corticosteroid molecule. 
 Thus discovery of an ideal vehicle is the potential target of research in this 
field of dermatology.22 
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OCCLUSIVE DRESSINGS 
 The permeability of steroid as we discussed earlier is enhanced under 
occlusion upto 10 fold .25 
 The various occlusive used in clinical practice include wet wraps – guaze or 
hydrocolloids 
 Occlusive dressings play a vital role in management of long standing 
dermatitis like atopic dermatitis which thus helps to minimize the used of long 
term corticosteroid therapy. 
 
ADVERSE EFFECTS 
SYSTEMIC 
The factors that facilitate systemic absorption include 
 high potent corticosteroid usage 
 duration of treatment more than 6 months  
 application on diseased skin with impaired barrier 
 using occlusive in addition 
 applying on large body surface areas  
 
Systemic absorption rarely occurs and if so, results in 
 Increased blood sugars, Cushings disease, femoral head osteonecrosis , and 
growth suppression in children 
 Rarely HPA axis suppression23 
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CHOOSING THE TOPICAL STEROID 
Key factors to be considered include: 
1) Know the disease : Correct diagnosis of the disease should be made in which 
there is reasonable evidence of efficacy. 
2) Know the drug: For selecting the drug- potency, delivery vehicle, frequency of 
application, duration of application should be kept in mind. 
 Long and Finlay, described a practical modalitity to measure the amount of 
topical steroid used for a specific area- termed as finger tip unit.26 
 1FTU is equal to 0.5g or ointment which corresponds to 2 palm surfaces. 
 
 
 
Figure – 5   Fingertip Unit 
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Table – 6 
SIDE EFFECTS OF TOPICAL CORTICOSTEROIDS 
Adverse effects Clinical presentation Underlying mechanism 
Epidermal thinning decrease in epidermal kinetic activity 
flattening of the dermoepidermal 
convulsions 
decrease in the thickness of keratinocyte 
layer 
Dermal Striae 
Easy bruisability 
Blot hemorrhage 
Melanocyte 
inhibition 
Reduced ground substance and collagen 
synthesis 
Risk factors include young age, 
potency, occlusion, location of 
application 
Combined Atrophy 
Telangiectasia 
Striae 
Purpura 
Stellate pseudoscars 
ulceration 
Loss of intercellular substance and 
dermal atrophy 
Decreased dermal matrix surrounding 
the blood vessels 
Contact allergy Allergic or irritant 
contact dermatitis 
More commonly observed in patients 
with long term dermatitis such as atopic 
dermatitis, stasis dermatitis, perianal 
dermatitis 
Ocular effects Exacerbation of 
herpetic ulcers  
Increased 
susceptibility to 
bacterial and fungal 
infections 
glaucoma/ cataract 
steroid eye drops andrarely due to 
potent steroid applications around eyes 
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Adverse effects Clinical presentation Underlying mechanism 
vascular effects rebound 
phenonmemnon 
perioral dermatitis 
rosacea 
fixed vasodilation 
 
Hair hypertrichosis - face 
& ears 
lanugo hair 
alopecia 
 
Infections increased incidence 
of fungal and 
bacterial infection 
folliculitis 
crusted scabies 
masking of 
microbial infections 
-Eg.tinea incognito 
 
effects owing to 
pharmacological 
properties 
tachyphylaxis 
steroid rebound 
steroid addiction 
non compliance 
excessive vasodilation on withdrawal 
Miscellaneous acneform eruption 
miliaria 
urticaria 
delayed wound 
healing 
hypo/hyper 
pigmentation 
milia27 
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SYSTEMIC EFFECTS (rare) include 
 HPA axis suppression 
 hyperglycemia 
 reduced bone mineral density 
 edema, hypocalcemia and hypertension 
occurs as a result of increased application of high potent steroids increased 
penetration - Eg. atopic children used under occlusion use in larger areas27 
 
 
SKIN ATROPHY 
 Commonest and can affect both epidermis and dermis.  
 Epidermis - changes in epidermis start 3-14 days of treatment, as a result 
of reduced epidermal size and deceased metabolic activity.  
 On continual application it can cause thinning of the stratum corneum and 
absent granular layer. Melanocyte function impairment occurs resulting in hypo 
pigmentation 
 Dermis - decreased fibroblast growth, reduced collagen synthesis, 
resorption of mucopolysaccharide ground substance in dermis, loss of connective 
tissue support of dermal vasculature. 
   
 Influencing factors - Age, body site, potency, occlusion 
 
 These changes are reversible but takes months.27 
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Table - 7 
VEHICLES USED COMMONLY AND THEIR ADVERSE EFFECTS 
 
 ADVERSE EFFECTS  CAUSATIVE COMPONENT 
Stinging sensation lactic acid, urea, formaldehyde, benzoic acid, 
cinnamic acid compound, sorbic acid 
Irritation Propylene glycol, alcohol, acetone 
Urticaria Formaldehyde, cinnamic acid compound  acetic 
acid, benzoic acid, sorbic acid 
Allergic contact dermatitis Propyl gallate, sorbic acid, parabens, 
formaldehyde27 
 
 All these Cutaneous effects are reversible except for atrophic striae which 
may be permanent. 
 
 Rebound effects though rare can occur after abrupt discontinuation of potent 
topical corticosteroid. The corticosteroids which cause vasoconstriction can cause 
excessive vasodilatation when it is withdrawn. 
 
 Understanding the drug deposition and penetration in the skin will help the 
clinican in prescribing appropriate duration and frequency of therapy.93 
 
 Hence optimizing the frequency of application reduces the adverse outcomes 
including tachyphylaxis and also reduces the expenses which thus improves 
patient satisfaction.95 
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 Moisturisers should be advised daily which can also be used as a sole therapy 
later. 27 
 
TACHYPHYLAXIS 
 It is a phenonmenon observed on long term use of topical steroids. 
 
 It’s the tolerance a person’s skin develops due to the vasoconstrictive effects 
of topical corticosteroids. After prolonged therapy – the dermal vessels do not 
constrict well which thus requires higher doses or much frequent application than 
before.96 
 
 The ability of these vessels return to normal 4 days after stopping therapy. 
 
 Hence a “weekend” or “pulse” therapy resolves this compliance issue or else 
it can be stopped for 4-7 days and restarted.23 
 
MISUSE 
 Misuse of topical corticosteroids is fairly common in India, as indicated by 
the proportion of patients visiting dermatologists with adverse effects of these 
drugs. skin lighteners and along with other irritating skin lightening agents.The 
adverse effects related misuse include perioral dermatitis, infantile gluteal 
granuloma, tinea incognito, impetigo incognito and apart from routine.97-100  It has 
also noted to delay the diagnosis of leprosyand erythrodermic psoriasis.28 
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ALLERGIC CONTACT DERMATITIS TO TOPICAL 
CORTICOSTEROIDS 
 
INCIDENCE 
 
 The hypersensitivity reactions to steroids are of two types - Immediate 
reactions47: occurring within 1 hour, Delayed - more than half an hour after drug 
administration. The latter being more common is discussed here.  
 
 On reviewing various literature reports the frequency of allergy is 0.2 to 5%. 
(3,4,13)
 Prevalence is extremely variable and is influenced by prescribing habits, 
awareness of topical steroid induced hypersensitivity among doctors, diagnostic 
procedures. 44-57 
 
 Patients with asthma have a higher incidence than with other conditions3 of 
the various risk factors - atopic dermatitis and stasis dermatitis ranks the 
commonest.29,108 
 
 
CLINICAL FEATURES 
 Contact allergy to topical corticosteroids needs a high index of suspicion, as 
clinical presentation is very subtle.11Acute weeping eczema is extremely 
uncommon.109 
41 
 
The various presentations include27 
 
1. Chronic eczema which gets worse over the yearsinspite of therapy and 
requirement of large amounts or more potent steroids although avoidance of 
aggravating factors. 
2. Improvement only with specific brands of steroids 
3. Requirement of oral steoids or other medications 
4. Aggravation of dermatosis on topical corticosteroid application 
5. Lack of expected outcome12 
 
 A common situation is the patient presents with prominent local adverse 
effects but with persistent complaints.10 
 
 Browne F. and S.M. Wilkinson suggests that all patients who have long 
standing or recurrent dermatitis like atopic dermatitis, stasis dermatitis or hand 
eczemas should at some point be tested for corticosteroid allergy.30 
 
DIAGNOSIS 
 Various methods of detecting corticosteroid hypersensitivity after a clinical 
suspicion is made includes8 
1. Patch test 
2. Repeated open Application Test74 
3. Intradermal testing75 
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4. Oral provocation tests31,78 
5. But before all this a detail history as to 92 
6. Duration of the primary diagnosis for which the topical steroid was used 
7. What are the various topical used in the past 
8. Duration of application 
9. Whether in combination 
10. Was it prescribed or obtained over the counter 
11. Nature of the medicament – cream, ointment etc., has to be obtained.  
12. With all this knowledge we are going to discuss about the most commonly 
employed investigation in practice 
 
PATCH TEST 
 Patch testing in a patient with suspected TCS induced allergy needs a in 
depth knowledge regarding its properties, concentrations that have to be used and 
the vehicles. Apart from this the controversies underlying the readings, edge 
effect, false positive and false negative results.3,32 
 
 A standard series including patients own medicament will be justified. 
Pitfalls in determinations of appropriate test methods relates to factors such as, the 
anti-inflammatory effect of corticosteroids, individuals having high sensitizing 
capacity, bioavailability of the uninvolved patch test site-back / upper arm and not 
the involved skin which has impaired barrier function. 
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 Usually the concentration of the corticosteroid is low in commericially 
available preparation, can result in contact hypersensitivity in diseased skin might 
result in negative outcome on patch testing. Merely increasing concentration of the 
patch test chemical does not increase its bio-availability.8 
 
 Allergy due to a topical steroid containing produce can be explained by 
various factors including  
 Excipients  (Preservatives, penetration enhancers) 
 Allergens in the packaging  (Nickel from the tube) 
 Active ingredients27 
 
 False negative reactions in the patch tests can be explained owing to its 
physicochemical properties: 
 
 Molecular and crystal size and lipophilicity. 
 
 Lesser concentration of allergen in the skin for hapten protein binding 
occurs when there is decreased penetration due to lesser solubility of the 
corticosteroid in the test solution.31 
 
 Regarding the optimal patch- test preparation, both the vehicle and 
concentration of allergen is involved. 32 
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VEHICLE FOR PATCH TEST: 
 The optimal vehicle is yet to be determined. There are controversies 
between two – ethanol and petrolatum.67-69 
 
 Equivalent patch test results are obtained in case of certain molecules such 
as tixocortol (Group A) and budesonide (Group B) whereas hydrocortisone 17 
butyrate yields better results only with ethanol 33,79 
 
CONCENTRATION 
 In patients who are weakly sensitized to TCS molecule, because of its anti-
inflammatory effect, it results in a negative response.70-72 
 If its too low – false negatives unless on eczematous site 
 If its too high - false negatives because of anti-inflammatory effect. 
 
 1% dilutions of allergen are more commonly used in various studies for 
patch testing topical corticosteroids. But Issakson et al suggested that in patients 
with weak sensitizing potentials lesser concentrations should be used to combat 
the pharmacological effect of topical corticosteroids as such.80-91 
  
 For example,0.1% tixocortolpivalate and 0.01% budesonide, 1% for 
hydrocortisone yields better results.8 
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THE READING 
 
 Delayed reading is recommended owing to its anti-inflammatory properties 
by numerous authors 20,73 
 
Table – 8 
PECULIAR REACTIONS SEEN IN CORTICOSTEROID PATCH TEST 
 
Peculiar reaction Clinical description Interpretation 
Edge effect Thin rim of erythema/ papules at 
the edge at 48 h reading 
High inflammatory effect under 
the chamber 
Non-palpable erythema Faint erythema at 48/96 h 
reading 
Low potency molecules. 
Becomes positive in day 7 or 
later 
Blanching  Localized pallor at 48 h reading Highly potent molecules in 
alcohol due to vasodilation. 
May become +/- later 
 
EDGE EFFECT 
 The anti-inflammatory effect that is more pronounced at the site than the 
edges where the diffusion is present resulting in lower concentration. Thus, results 
in peripheral erythema or papules around the patch applied site. This is considered 
positive in case of corticosteroid patch testing.14 
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CROSS REACTIVITY 
 
 Dooms Goosens in 1986 observed that patients reacted to tixocortol in 
patch test where the molecule was not available in the country.58  This is explained 
by its structural similarity to the parent molecule – hydrocortisone.37 This was 
further confirmed when these patients tested positive to intradermal 
hydrocortisone injections. Similar cross-reactions were observed with budesonide 
and triamcinolone.27 
  
 Before discussing about the cross reactivity patterns certain factors as to 
how corticosteroids induce allergy and knowledge on the chemical structure is 
needed. 
 
CORTICOSTEROIDS AS HAPTENS AND POTENTIAL CROSS 
REACTIVITY 
 
Factors that determine the recognition of corticosteroid molecule includes 
 
 physicochemical structure of the molecule, to which gropu it belongs etc., 
The spatial geometry and the volume occupied by the molecules determine the 
receptor binding. 
 
True cross reactivity can be explained by the following 
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Considering A as a sensitizing compound and B as a triggering factor 
 A,B are similarphysicochemically 
 A is metabolized to forma substance which is identical to B and vice versa 
 Both A,B can result in similar substance on metabolisation 
co-sensitisation are thus mostly explained by these cross allergic phenomenons.16 
Non fluorinated corticosteroids binds to arginine in the keratinocyte than 
fluorinated corticosteroids because of rapid metabolic degradation. 
 
PHENONMENON OF CROSS REACTION 
 
 
The same T-cell receptor can bind to 2 different molecules which are 
structurally and chemically similar. 
 
Group sensitization – wherein a series of similar molecules often give rise 
to cross reactions in patients.16 
 
The conformation of corticosteroids of the 4 groups analyzed and put forth 
2 hypothesis. 
1) Corticosteroid molecules are possibly metabolized in similar ways and 
hence destined to interact with similar type of receptor 
2) Esters in C 21 are readily hydrolysed to give the free alcohols whereas  
esters in C17 are more resistant to hydrolysis due to strong steric 
hinderence.34 
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Eg. Tixocortol 21 pivalate – free thiol group in C 21 whereasaclometasonehas in 
17,21  
 
All molecules have multiconformational analysis show that the electronic 
shape that defines the different groups A,B,D and not C.  
 
 The volume occupied by specific groups on α face of ring D seems to be 
critical for the molecular recognition of corticosteroids, while the modifications of 
the other parts of the molecule seem to have little effect on the recognition 
patterns.8 
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Figure - 6 
SITES IN CORTICOSTEROID MOLECULE THAT DETERMINES 
CROSS REACTIONS 
 
 
The allergen is not the steroid on its own but its degradation product36 
Corticosteroids undergo degradation to reactive glyoxal that then binds with 
arginine in the keratinocytes  to form antigen.  
This glyoxal is formed on the C17 side chain on C21 position. 
On topical application, the esterase that is present in the epidermis splits any esters 
present in the molecule resulting in C21 OH group 
C21 ester dicarbolic acid- unaffected 
C21 ester carbolic acid - > 60% hydrolysed within 30 min  (affected) 
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Figure – 7  Illustration of Group Specific nomenclature 
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The allergens we used were of the chemotechnique series, which is listed as 
follows: 
Table – 9 
LIST OF ALLERGENS USED 
ALLERGEN CONC.% 
Budesonide  0.01 
Betamethasone-17-valerate  1 
Triamcinolone acetonide 1 
Aclolometasone-17,21-dipropionate 1 
Tixocortol-21-pivalate  0.1 
Clobetasole 17 propionate  1 
Dexamethazone-21-phosphate disodium  1 
Hydrocortisone-17-butyrate  1 
 
C16/17 substitutions influence cross reactivity. 39 
 Different isomeric forms of budesonide have shown to resemble both the 
acetonide structure as well as C17 esters – this explains as to why budesonide is a 
good patch test screen.63-65 
 90% of individuals who react to budesonide cross react to multiple 
antigens. 40 
 50% of individuals who react to tixocortol cross react.38,43 
Thus multiple immune recognition sites determine whether a substance cross-
reacts or not.61,64 But this does not happen always, and hence not a rule.36 
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Table – 10  
COMMONLY USED TOPICAL PREPARATIONS BY 
DERMATOLOGISTS IN OUR INSTITUTION 
 
Brand name Generic name Group (coopman) 
Lobate 
Tenovate 
Clobetasol propionate 0.05%  D1 
Betagel Betamethasone dipropionate 0.05%  D1 
Halovate Halobetasol propionate 0.05%  D1 
Momate 
Elocon 
Mometasonefuorate 0.1%  D1 
Betnovate Betamethasone valerate 0.1%  D1 
Diprovate Betamethasone dipropionate D1 
Flutivate Fluticasone propionate D1 
Dexamet 
Sofradex 
Dexamethasone C 
Desowen Desonide 0.05%  B 
Flucort Fluocinoloneacetonide B 
Tess Triamcinolone acetonide B 
Lycor Hydrocortisone cream0.5% and 1%  A 
 
 
Apart from these, numerous combination creams are available including 
double, triple and quadruple type of formulations. 41Listing of which is tedious. 
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Those include combinations of salicylic acid and steroids, antibiotic and 
steroids, antifungals and steroids, all three of them etc., Triple combinations with 
hydroquinone and retinoic acid are a main stay of therapy in melisma. 
 
Ophthalmic, intranasal, inhalational, intralesional9 and other preparations 
for steroids and parenteral 4,60formulations should also be taken into account as 
these are reported to cause sensitization. Oral intake of hydrocortisone and 
methylprednisolone in topically sensitized patients resulting in delayed systemic 
reactions are rarely noted.94,59 
 
 Apart from these entire groups where there is labeling, off label uses are 
there which are commonly misused which includes shampoos, cosmetics etc., 
Apart from this components of topicals steroid formulations which are 
documented in the past to cause ACD include 
 Steroid molecule (active ingredient) 
 Propylene glycol 
 Parabens 
 Benzyl alcohol 
 Benzalkonium chloride 
 
Thus delineating that it is crucial to patch test with individual components 
when the corticosteroid panel is negative.3,12 
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MATERIALS AND METHODS 
 
STUDY DESIGN 
 Open label prospective observational study 
 
STUDY PERIOD 
 This observation was held  during a period of 1 year  in patients  suspected 
to have corticosteroid contact hypersensitivity clinically after obtaining clearance 
from the ethical committee. 
 
STUDY POPULATION  
 
 All patients attending our dermatology out- patient department-
males/females, with history of topical steroid application, who do not respond to 
/or aggravate with topical corticosteroids. 
 
Inclusion Criteria 
  24 patients aged 14-83 with suspected corticosteroid allergy with history of 
application of topical steroids were included in this study  
 
Exclusion Criteria 
 Patients on systemic or oral steroids(>20mg/day) immunosupressants 
 Pregnant and lactating mothers 
 Patients with skin lesions on the patch test sites – back and/or arm 
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SAMPLING METHODS 
 
 Patients were included after obtaining written informed consent 
 Patch tests were done on the upper back or arm whichever applicable using 
Finn chambers with the corticosteroid series+/- ISS provided by the 
Chemotechnique diagnostics (AB Sweden).  
 Patch left in place with micro pore tapes for atleast48 hours and advised not 
to involve in vigorous activities or allow it to come in contact with water. 
 Grading is according to (ICDRG) scale Day 3 (D3), Day 5(D5) and Day 
7(D7) 
  In addition to this, whenever possible the patient’s own medications will 
be applied –whenever possible the individual allergens were tested if 
patient had used combination creams. 
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Table -11 
CORTICOSTEROID SERIES 
S.No. ANTIGEN % 
01 Control     
02 Budesonide  0.01 
03 Betamethasone-17-valerate  1 
04 Triamcinolone acetonide 1 
05 Tixocortol-21-pivalate  0.1 
06 Aclolometasone-17,21-dipropionate  1 
07 Clobetasole 17 propionate  1 
08 Dexamethazone-21-phosphate disodium salt  1 
09 Hydrocortisone-17-butyrate  1 
 
PATIENTS OWN TOPICAL MEDICATIONS: 
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DATA ANALYSIS /OUTCOME EVALUATION  
 
 Data obtained have been recorded and documented in the department file. 
 Prevalence and clinical patterns of steroid hypersensitivity was determined 
 Pamphlets have been issued to the patients containing the information about 
the allergen with which he/she has tested positive in patch testing and list of 
common medicaments containing the allergen. Also, in brief about possible 
cross allergies and hence importance of informing the treating physician/ 
dermatologists 
 Hence we could thus educate the patient on prevention of exposure to the 
allergen. 
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RESULTS 
 
Table - 12 
AGE SEX DISTRIBUTION 
 
Age 
in years 
Sex 
Total Percentage % Male Female 
10 - 20 1 0 1 4 
21 - 30 1 2 3 12.5 
31 - 40 5 2 7 29 
41 - 50 1 1 2 8.3 
51 - 60 2 0 2 8.3 
61 - 70 4 0 4 16.9 
71 - 80 3 0 3 12.5 
81 - 90 0 2 2 8.3 
Total 17 7 24  
 
Inference:   males > females ; commonest age 31-40 
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Figure – 8 Age Group 
 
Male: Female Ratio 
 
 
 
Figure – 9 – Male Female Ratio 
 
Males – 70.8%, Females 29.2 % 
17 
7 
60 
 
 
Table - 13 
DURATION OF COMPLAINTS FOR WHICH TOPICAL STEROID 
WAS APPLIED 
 
Duration of complaints 
in months 
No. of patients % No.of patients with positive patch test % 
0 - 6 6 25 0 82.4 
6 - 12 2 8.3 0 58.3 
12 - 24 6 25 0 71.4 
24 - 36 5 21 0 62.5 
36 - 65 3 12.5 3 83.3 
65 - 72 2 8.3 1  
 
 
 Inference: Possible correlation of duration of the complaints directly 
proportional to the patch test positivity.  
 
 Patch test positivities are noted in duration more than 3 years. 
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Figure – 10 
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Table - 14 
PRIMARY DIAGNOSIS 
 
S.NO Primary diagnosis Number of patients 
Percentage 
% 
1. Palmoplantarpustulosis 2 8.3 
2. Bullous pemphigoid 1 4 
3. Lichen simplex chronicus 1 4 
4. Perianal pruritis 2 8.3 
5. Atopic dermatitis 7 29.6 
6. Seborrheic dermatitis 1 4 
7. Allergic contact dermatitis 4 16.9 
8 Psoriasis 1 4 
9 Stasis dermatitis 4 16.9 
10 Hailey Hailey disease 1 4 
 
 
Inference: most common among atopic followed by stasis and allergic contact 
dermatitis 
 
 
 
 
63 
 
 
 
 
Figure – 11  
 
 
 
1-7 Indicates the number of patients with the particular diagnosis 
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Table - 15 
 
PAST TREATMENT DETAILS 
 
S.No Topical preparations Number of patients Applied Percentage 
1. Emollient  23 95.8 
2. Antibiotics 10 42 
3. Steroid 24 100 
4. Combination 7 29 
 
Inference: All patients were on on steroid molecule or other.  
                    All were on emollients except a case of bullous pemphigoid 
 
7 patients were on antibiotic steroid combination 
 
 
 
Figure - 12 
65 
 
Table - 16 
DETAILS OF TOPICALS 
 
S.No Steroid brand name(generic name Antibiotic 
combinations 
1 Diprovate         (Betamethasone dipropionate) 
Flutivate           (Fluticasone propionate) 
- 
2 Propysalic NF (Clobetasol propionate 0.05%) 
Flucort H          (Fluocinoloneacetonide) 
 T-Bact 
(mupirocin) 
3 Momate XL      (Mometasonefuorate 0.1%) 
Dipgenta           (Clobetasol propionate 0.05%) 
 T-Bact 
(mupirocin) 
4 CFT-CP -           (Fluocinoloneacetonide) 
 
CFT-CP 
ciprofloxacin, 
clotrimazole, 
neomycin 
5 Tenovate            (Clobtasol propionate 0.05%)  
6 Betagel              (Betamethasone diprop 0.05%)  
7 Momate              (Mometasonefuorate 0.1%)  
8 Halovate F          (Halobetasol propionate 0.05%) Haolvate F- fusidic 
acid 
9 Tenovate            (Clobetasol propionate 0.05%)  
10 Halovate            (Halobetasol propionate 0.05%) 
Psoricort             (Clobetasol propionate 0.05%) 
Dexomet             (Dexamethasone) 
Momate              (Mometasonefuorate 0.1%) 
Betnovate GM    (Betamethasone valerate 0.1%) 
Betadine 
Betnovate GM - 
gentamycin 
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11 Flutivate              (Fluticasone propionate) Betadine 
T- Bact 
(mupirocin) 
12 Sebowash -          (Fluocinoloneacetonide)  
13 Tenovate            (Clobetasol propionate 0.05%)  
14 Tenovate             (Clobetasol propionate 0.05%)  
15 Betnovate            (Betamethasone valerate 0.1%)  
16 Flutivate              (Fluticasone propionate)  
17 Halobaetasol        (Halobetasol propionate 0.05%) T- Bact 
(mupirocin) 
18 Momate              (Mometasonefuorate 0.1%)  
19 Fucibet               (Betamethasone valerate 0.1%)  
20 Betnovate GM    (Betamethasone valerate 0.1%) Betnovate GM 
(Gentamycin) 
21 Topinate               (Clobetsol propionate 0.05%)  
22 Betagel G             (Betamethasone dipropion0.05%) Betagel G 
(Gentamycin) 
23 Flutivate              (Fluticasone propionate) 
Elocon                 (Mometasonefuorate 0.1%) 
Desowen              (Desonide 0.05%) 
 
24 Tenovate            (Clobetasol propionate 0.05%)  
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Table – 17 
 
PRESENTING COMPLAINTS 
 
S.NO Presenting Complaints Number of patients Percentage% 
1. Poor / Failure of response 20 83.3 
2. Worsening 4 16.7 
 
 
 
 
 
Figure -13 
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Table - 18 
FREQUENCY OF ALLERGEN POSITIVITY IN THE 
CORTICOSTEROID SERIES 
 
S.No. Allergen No. Of Patients Percentage 
1 control 0 0 
2 Budesonide 0.01% 0 0 
3 Betamethasone 17 valerate 1% 0 0 
4 Triamcinolone acetonide 1% 1 4 
5 Tixocortol-21-pivalate 0.1% 2 8.3 
6 Alclomethasone 17,21 dipropionate 1% 0 0 
7 Clobetasol 17 propionate 1% 0 0 
8 Dexamethasone-21-phosphate disodium 1% 1 4 
9 Hydrocortisone-17-butyrate 1% 0 0 
Total 4 16.3 
 
Inference: Of the 24 patients, 4 patients tested positive (16.3%).  
Tixocortol is the most common allergen in this study which was found to be 
positive in 2(8.3%) followed by Dexamethasone in 1(4%) Triamcinolone in 1(4%) 
 
Apart from this of the allergens tested using Patient’s own products - flutivate and 
desowen was positive in 1(4%) patient. 
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Figure - 14 
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DISCUSSION 
 
 Topical corticosteroids constitute the main armamentarium in the treatment 
of various dermatological indications. 32 This most useful anti-inflammatory drug 
has been studied extensively in the recent past in respect to its hypersentivity 
reactions.12 
 
 Inspite of the fact that corticosteroids decrease the Langerhans cell 
population and thus their immune functions, it cannot prevent its hypersensitivity.  
Type IV (delayed) hypersentivity is more common than Type I hypersensitivity 
react ions.11 
 
 The corticosteroids are compounds with low molecular weight and are 
haptens that only on binding to proteins in human body induce a hypersensitivity 
reaction.31 In 1980 Bundgaard studied the properties of corticosteroids which get 
degraded to corticosteroid glyoxal 21- dehydrohydrocortisone, which reacts with 
skin proteins like guanidyl resulting in ketoaldehydes. 
 
 Groups of arginine and results in formation of the antigenic complex. On 
this background if we look into the carbon substitutions in detail the non 
fluorinated corticosteroids degrades and reacts with arginine more rapidly than the 
fluorinated corticosteroids.36 
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The first report of the description of corticosteroid allergy is in 1959. 37The 
incidence of these allergic contact dermatitis ranges from 0.2 to 5%.3 A study by 
north American contact dermatitis group NACDG reported it to be 3.1% and in 
England the same was estimated to be 4.9%.12 
 
 This huge variability relates to easy availability, the frequency and amount 
of of the topical steroid used, geographic variation, type of steroid used and the 
different methodologies of patch testing in terms of the panel, vehicle, 
concentration and reading times.61-77 
 
 The scenario in Asia is such that only limited data are available in this 
respect which demands more extensive studies in establishing the patterns of 
allergy in the asian population. 3A study in South east Asia revealed a positivity 
rate of 3.29% amongst all patch tested patients over a 10 year period in 
Thailand.110 
 
 Indian scenario is also influenced by the fact that there are numerous 
double and triple combination creams, including Kligmann’s formula  in the 
market over the counter and are available in numerous fairness creams and is used 
as cosmetic preparartions.28 Very poor awareness regarding the need for reading 
labels and importance of information on how to use and duration of application.  
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 There is no data on the exact prevalence of the topical steroid induced 
contact dermatitis in our country. 28 
 
 The clinical picture varies from modest inflammatory changes to frank 
dermatitis with exudative lesions being fairly uncommon.30 The subtle 
presentations include an dermatosis that is unresponsive to steroids or only 
improve on specific brands of steroids ; worsening of preexisting dermatosis on 
application of topical steroids.12 
  
 The patients who are sensitized to corticosteroids are most often allergic to 
other substances like preservatives and antibiotics. 8 
 
 Degreaf, Goosens et alobserved that co-sensitisation occurred in 82% of 
patients with atleast one other allergen. 50 
  
 Of the various diagnostic modalities patch testing is the major method of 
detecting Type IV hypersensitivity- practical and feasible.45,77 In patients where 
corticosteroid hypersensitivity is suspected the standard patch is applied and in 
addition to the 48 and 72 hours a delayed reading is absolutely necessary without 
which 30%of the allergic reactions are likely to be missed.20,73 
 
 This may be explained by the fact that the intrinsic anti-inflammatory 
action may suppress or delay the cutaneous response. 37 
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The pattern of patch test positivity in corticosteroids is influenced by 
numerous factors as discussed earlier. 66-73These include: 
 test concentrations 
 vehicle chosen 
 necessity of late readings 
 edge effect 
 false negative and  
 false positive reactions 
 
 Considering all these factors, and the classification of corticosteroid by 
Coopman based on the chemical structure35,36 
 
We review our patient results of corticosteroid patch testing which was 
conducted in 24 patients with suspected corticosteroid allergy and positive 
outcome obtained in 4 of them (16.7%) 
 
 
Reviewing the demographic data  
 
 The commonest age group of involvement was on the third and fourth 
decade (31-40 years) and males (29.2%) affected more than females (70.8%).  
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 Longer duration of application of topical steroids was associated with more 
incidences of corticosteroid patch test positivity. In our study all positivities were 
in patients who applied topical steroids for more than 3 years. Similar observation 
was made by Gonul M who noticed ACD to TS was more common in patients 
who used it 1 years or more. 30 
 
 Of the various causes of patients presenting with complaints that gave rise 
to suspicions of corticosteroid allergy the most common diagnosis in these 
patients were Atopic dermatitis followed by stasis dermatitis and allergic contact 
dermatitis to other substances. Similar results were found in study done by M. 
Baeck et al8 and also MuzeyyenGonul et al. 30This can also be explained by the 
chronicity of the condition and requirement of long term application of 
corticosteroids in these patients. 
 
 All patients were on multiple topical preparations. Which included 
emollients and topical steroids and considerable about were combinations. 
Combinations were either steroids with antibiotics or steroids with antibiotics and 
antifungals.  
 
 In addition to the routine corticosteroid series we also patch test for patients 
own medications. 12,87 
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This resulted in some interesting observations.  
 
 For example, in Case No. 23 a female patient who is a case of allergic 
contact dermatitis to kumkum (Patch test proven) who was on topical steroids on 
and off for long duration prior to our investigation presented with worsening of 
lesions on applingflutivate. Now keeping in mind the fact that fluticasone is not 
present in our coricosteriod panel ( chemotechnique ) we went ahead with our 
routine procedure – costicosteroid patch test and patient’s own patch test which 
included fluticasone (Group D1)  (as Flutivate ointment, GSK) Desonide (Group 
B) (as Desowen cream) and mometasone (Group D1) (as Elocon ointment).  
 
 She tested positive initially to tixocrtol on day 3 and 5. Flutivate was 
positive throughout; Desowen disappeared after day 3 Elocon tested negative.  
Now, on reviewing the literature, there are studies stating that Group A 
(tixocortol) cross reacts with group B and group D1 (fluticasone) . 
 
 But all this said and done, a study by Wilkison and Baeck44 as quoted by 
Fisher’s have included Group C and mometasone and fluticasone as 
“hypoallergenic” which is attributed to the following facts. Novel substitution at 
C17 in mometasone and fluorine at C6 and C9 rather than C17 are thought to be 
responsible for lesser cross reactivity.7 
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 There are other articles also supporting the fact that fluticasone is a rare 
sensitisor. 101 
 
 In Case No. 16, a male patient who presented with perianal dermatitis who 
tested positive to triamcinolone which was consistent from Day 3 to Day 7 tested 
negative to his own preparation (Flutivate). But we should keep in mind that the 
flutivate was his current preparation and limited data was available as of his 
previous therapy. 
 
 As we discussed earlier there are studies stating cross reactivity between 
group A, B, D1. Hence that could explain the reaction to triamcinolone (Group B) 
which is not a commonly used commercial drug on skin.34 
 
 Apart from this , 2 patients – Case No. 20 and Case No. 12 who had reacted 
to hydrocortisone and tixocortol respectively on Day 3 had no reactions at the site 
on Day 5 and Day 7.  
 
 Considering this, on our literature review although there are evidences 
supporting late reading,12,37 a study by Mark D.P Davis who conducted 
corticosteroid patch testing in 1188 patients who came across similar problem 
were they had to exclude the reactions which appeared on intial evaluations as 
irritant stated that it could thus be possible that few of these reactions which were 
interpreted as irritant might be a positive reaction. They also observed that in 
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addition Day 7 readings detected only an additional 2 out of the 135 positive 
patch patients. Thus concluded that in their experiences extended reading are of 
limited value. 45 
 
 One should also keep in mind the fact that all these patients react to the 
commercially available preparations which consists of vehicles which can increase 
the penetration of the corticosteroid molecule that done in patch test with neutral 
vehicle. 3 
 
 Apart from this 2 patients also reacted to T- Bact ointment.  
 
 But a much detailed evaluation and preservative series patch testing is 
needed in these cases to determine the exact cause.  
 
 Considering all of the above mentioned facts corticosteroid patch testing 
has numerous pitfalls which are debatable at multiple levels and needs a in depth 
understanding of the nature of the molecules and the response of the patients. Any 
lab investigation cannot reproduce the same allergic response is a fact.76 
 
 All 4 patients who tested positive to corticosteroid molecules were 
explained regarding the avoidance of allergens and also counseled regarding 
possible cross reactivity and that to inform every treating doctor the same. 
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 Moreover according to M.Baeck et al,  rarely can a dermatologist achieve a 
prescription which can avoid the corticosteroid allergy because of increased 
frequency of cross sensitisation.8 
 Further studies are still needed in regard to the same. 
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CONCLUSION 
 
 Contact hypersensitivity to corticosteroids is thus a clinical entity that has 
to be kept in mind by all treating doctors. In our study we detected that 16.7% - 4 
out of 24 patients with suspected corticosteroid hypersensitivity tested positive.  
Hence high index of suspicion and awareness regarding the clinical patterns, cross 
reactivity and need for diagnosis of contact hypersensitivity to topical 
corticosteroids is thus mandatory. The patients who are diagnosed to have 
corticosteroid hypersensitivity in the patch test results should be counseled 
appropriately so as to achieve a better therapeutic outcome in both systemic as 
well as local corticosteroid therapy. 
 
 
 
 
 
 
  
 
 
 
 
 
 
39 year old female patient with recurrent 
scaling and fissuring of hands who was 
treated with multiple steroids, who initially 
responded and later had a poor response 
was patch testing with both ISS and steroid 
series. ISS revealed nickel sensitivity and 
steroid series revealed sensitivity to 
tixocortol 21 pivalate. 
  
 
 
 
 
 
 
 
 
 
Day 5 
Day7 
 
  
 
 
 
 
46 year old female patient a case of allergic contact dermatitis to kumkum
treated with steroids in past which initially responded and now aggravated 
corticosteroid revealed tixocortol 21 pivalate positivity and on testing with her own medications 
flutivate positivity 
 of long duration who was 
– patch test with 
 
-
  
 
Desowen (Pt’s own) 
Flutivate (Pt’s own)
Tixocortol 21 pivalate
Day 3 
 
 
 
 
 
  
Flutivate (Pt’s own)
Flutivate (Pt’s own)
 
 
 
 
Triamcinolone acetonide
 Day 7 
Day 3 
Triamcinolone acetonide
 
 
Day5  
Triamcinolone acetonide
 
52 year old male who presented with perianal 
dermatitis of long duration who was treated with 
steroids and combinations in past which initially 
responded and now aggravated.
positive to triamcinolone acetonide in the 
corticosteroid series  
 
 He tested 
  
 
 
 
 
Betamethasone 17 
valerate 
 
  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
ISS (if required)
 
 
  
 
 
 
 
 
 
 
 
Steroid series Steroid series +pt’s own 
 
 
  
 
 
 
 
LIST OF ANTIGENS IN CHEMOTECHNIQUE SERIES USED FOR PATCH TESTING
 
 
Sl.No. name age sex hosp.no address - localitydur tionof topical steroid application in monthstopical steroid usedsteroid usage
1 rangaraj 61 M 13/076051Pollachi 12 diprovate, flutivate1
2 bakthavacjalam68 M 04/006608ondipudur 4 propysalic NF, Flucort H1
3 palaniammal 83 F 14/004532tirupur 4 Momate XL, Dipgenta1
4 gunasekaran 55 M 14/006194erode 4 CFT_CP(Fluocinolone)1
5 muthukumarasamy71 M 14/038945ariyalur 1 Tenovate 1
6 loganathan 80 M 14/042390trichy 5 betagel 1
7 jennifer 26 F 13/018757tirupur 3 MomatF 1
8 radhabai 81 F 04/037342peelamedu 2 Halovate F 1
9 raj 39 M 14/014809nammakal 1 Tenovate 1
10 murugesan 64 M 12/077324Pollachi 3 Halovate,Psoricort,Dexomet1
11 subramaniam 76 M 13/059342erode 3 Flutivate 1
12 subramaniam 31 M 02/025655madurai 1 Sebowas 1
13 shankar 38 M 15/011004nammakal 2 Tenovate 1
14 kalaiselvi 39 F 05/000456udayampalam 2 Tenovate 1
15 jithinkumar 27 M 12/049327trivandrum 3 Betnovate 1
16 muthumanickam52 M 15/011529salem 4 Flutivate 1
17 padmavathy 38 F 15/016167coimbatore 3 Halobetasol 1
18 deepthi 21 F 15/020022coimbatore 2 Momate 1
19 ramesh 35 M 11/071867erode 1 Fucibet 1
20 prem nasir 48 M 15/019077dindugal 4 Betnovate GM 1
21 pradeep chandran34 M 14/069917mettupalayam 2 Topinate 1
22 annamalai 13 M 15/019004tirupur 3 Betagel G 1
23 saritha 46 F 15/026075vellore 4 Flutivate,Elocon,Desowen1
24 kandhaswamy 62 M 13/011567kandhaswamy 5 Tenovate 1
emollient usageantibiotics usedantibiotics persay or combination usagecombinations usagepo r responsew rseningon immunosuppressants / pregnancydiagnosi controlbud sonidebetamethasone 17 valerate
1 0 0 1 0 0 palmoplantar pustulosis0 0 0
1 T- bact 1 0 1 0 0 bullous pemphigoid0 0 0
1 T- bact 1 0 0 1 0 lichen simplx chrnoicus0 0 0
1 CFT-CP 1 1 1 0 0 perianal pruritis0 0 0
1 0 0 1 0 0 atopic eczema0 0 0
1 0 0 1 0 0 atopic eczema0 0 0
1 0 0 1 0 0 atopic dermatitis0 0 0
1 Fusidic acid(Haolvate F)1 1 1 0 0 atopic dermatitis0 0 0
1 0 0 1 0 0 stasis dermatitis0 0 0
1 Betadine, Gentamycine (Betnovate GM)1 1 0 1 0 atopic dermatitis0 0 0
1 0 0 1 0 0 atopic dermatitis0 0 0
1 T-bact,Betadine 1 1 1 0 0 seborrhoeic dermatitis0 0 0
1 0 0 1 0 0 palmoplantar pustulosis0 0 0
1 0 0 1 0 0 Allergic contact dermatitis0 0 0
1 0 0 1 0 0 psoriasis 0 0 0
1 0 0 0 1 0 perianal dermatitis0 0 0
1 T-Bact 1 0 1 0 0 allergic contact dermatitis0 0 0
1 0 0 1 0 0 allergic contact dermatitis- footwear0 0 0
1 0 0 1 0 0 hailey hailey0 0 0
1 Gentamycin (Betnovate Gm)1 1 1 0 0 stasis dermatitis0 0 0
1 0 0 1 0 0 stasis dermatitis0 0 0
1 Gentamycin (Betagel G)1 1 1 0 0 atopic dermatitis0 0 0
1 0 0 0 1 0 allergic contact dermatitis to kumkum0 0 0
1 0 0 1 0 0 stasis dermatitis0 0 0
triamcinolone acetonidetixocortol 21 pivalatealclomet sone 17,21 dipropionateclobetasol 17 r i atedexamethasone 21 phosphate disodiumhydrocortisone 17 butyratePATIENTS OWN
0 0 0 0 1 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 1 0 0 0 0 0
0 0 0 0 0 0 0
1 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 1 0 0 0 0 1-FLUTIVATE
0 0 0 0 0 0 0
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                                      ABBREVIATIONS 
 
CS- CorticoSteroids 
TCS-   Topical corticoSteroids 
CD -    Contact dermatitis 
ICD -   Irritant contact dermatitis 
ACD-  Allergic Contact Dermatitis 
DTH-   Delayed type hypersensitivity 
Ig–Immunoglobulins 
CD-Cluster of Differentiation 
h -         hours (in relation to reading of patch test) 
ICDRG  - International Contact Dermatitis Research Group 
DC -      Dendritic cells 
LCs-      Langerhans cells 
APCs-   Antigen presenting cells 
IL-         Interleukins 
IFN-      Interferons 
TNF-     Tumor necrosis factor 
Pts-        Patients 
ROAT- Repeated open application test 
HPA-Hypothalamo pitutary axis 
FTU-Finger Tip Unit 
OH-Hydroxal 
Master chart codes – o – Negative   1-Positive 
Xg;gjy; gotk; 
 
njjp          
 
mfpyh f. Mfpa ehd;  PSG kUj;Jtf;fy;Y}hpapd; njhy; ghy;tpid ; ;; ;; ; kw;Wk; ; ;; ;; ;
bjhGneha;;;;  Jiwapd; fPH;  “rUkj;jpy; Vw;gLk; mhpg;g[ neha;f;F ePz;l ehl;fs; ; ; ; ; ; [ ; ; ; ; ;; ; ; ; ; [ ; ; ; ; ;; ; ; ; ; [ ; ; ; ; ;
!;Ouha;L vDk; kUe;J jltpa[k; Fzkilahj nehahspfSf;F vt;tif  !;Ouha;L ; ; ; ; [ ; ; ; ; ;; ; ; ; [ ; ; ; ; ;; ; ; ; [ ; ; ; ; ;
kUe;JfSf;F xt;thi; ; ;; ; ;; ; ; t cs;sJ  vd;W KJfpy; xl;og;ghh;f;Fk; xt;thik; ; ; ; ; ; ; ; ;; ; ; ; ; ; ; ; ;; ; ; ; ; ; ; ; ;  fz;lwpa[k; ; [ ;; [ ;; [ ;
ghpnrhjid” vd;w  jiyg;gpy; Ma;t[ nkw;bfhs;s cs;nsd; 
 
vd; Ma;t[ tHpfhl;o; ; [ ;; ; [ ;; ; [ ;  :   kU. rp.Mh; _dpth!; 
Ma;t[ nkw;bfhs;tjw;fhd mog;gil; [ ; ; ; ;; [ ; ; ; ;; [ ; ; ; ;  
 
 rUk mhpg;g[ neha;f;F kUe;jhf cgnahfg;gLj;jgLk;  !;Ouha;Lf;F  xt;thik 
,Ug;gpd; rpwe;j Kiwapy; mhpg;g[ nehia Fzg;gLj;j KoahJ. 
 
Ma;tpd; nehf;fk;; ; ; ;; ; ; ;; ; ; ;  
 ,e;j Ma;tpd; \yk; mt;btht;thik bghUl;fis jtph;g;gjhy; rpwe;j 
Kiwapy; rUk mhpg;g[ nehia Fzg;gLj;j Koa[k;. 
  
Ma;tpy; g';F bgWk; egh;fspd; vz;zpf;if; ; ; ; ; ; ; ;; ; ; ; ; ; ; ;; ; ; ; ; ; ; ;   :   30 egh;fs; 
Ma;t[ nkw;bfhs;Sk; ,lk; [ ; ; ;; [ ; ; ;; [ ; ; ; ; :   gp.v!;.$p kUj;Jtkid/  
njhy; ghy;tpid kw;Wk; bjhGneha; Jiw 
          
Ma;tpd; gyd;fs; ; ; ; ;; ; ; ;; ; ; ; : 
   
 !;Ouha;L xt;thik mwpe;J bfhz;L mtw;iw jtph;f;fyhk;. 
 
Ma;tpdhy; Vw;gLk; mbrsfhpa';fs; ; ; ; ; ; ;; ; ; ; ; ;; ; ; ; ; ; / gf;f tpist[fs;; ; [ ;;; [ ;;; [ ;; : 
 
 ,g;ghpnrhjidapd; bghGJ xU rpyUf;F mhpg;g[ Vw;gl tha;g;g[ cs;sJ.  
mJt[k; \d;W ehl;fs; kUe;J cl;bfhs;Sjy; \ykhf Fzkila[k;. 
 
 
  
 ,e;j Ma;tpy; fpilf;Fk; jfty;fs;  10 tUl';fs; ghJfhf;fg;gLk;.  ,it ntW 
ve;j Ma;tpw;Fk; gad;gLj;jg;gl khl;lhJ.  ve;j epiyapYk; c';fisg; gw;wpa 
jfty;fs; ahUf;Fk; bjhptpf;fg;gl khl;lhJ.  ,it ,ufrpakhf itf;fg;gLk;. 
 
,e;j Ma;tpy; g';nfw;f xg;g[f; bfhs;Stjhy; ve;jtpjkhd gyDk; c';fSf;F 
fpilf;fhJ.  ve;j neuj;jpy; ntz;LkhdhYk; Ma;tpypUe;J tpyfpf; bfhs;Sk; 
chpik c';fSf;F cz;L. Ma;tpypUe;J tpyfpf; bfhs;tjhy; c';fSf;F 
mspf;fg;gLk; rpfpr;irapy; ve;j tpj khw;wKk; ,Uf;fhJ. 
 
,e;j Muha;r;rpf;fhf c';fsplk; rpy nfs;tpfs; nfl;fg;gLk; / rpy ,uj;j 
khjphpfs; my;yJ jpR khjphpfs; vLf;fg;gLk;. 
 
nkYk; ,e;j Ma;tpy; g';F bfhs;tJ c';fs; brhe;j tpUg;gk;.  ,jpy; ve;j  
tpjf; fl;lhaKk; ,y;iy.  eP';fs; tpUg;gg;gl;lhy; ,e;j Ma;tpd; Kot[fs; 
c';fSf;Fj; bjhpag; gLj;jg;gLk;. 
 
Ma;thshpd; ifbahg;gk; : 
njjp  : 
 
Ma;t[f;Fl;gLgthpd; xg;g[jy;; [ ; ; ; ; [ ;; [ ; ; ; ; [ ;; [ ; ; ; ; [ ; 
ehd; ,e;j Muha;r;rpapd; nehf;fk; kw;Wk; mjd; gad; ghl;oidg; gw;wp 
bjspthft[k; tpsf;fkhft[k; bjhpag;gLj;jg;gl;Ls;nsd;.  ,e;j Muha;r;rpapy; g';F 
bfhs;st[k; ,e;j Muha;r;rpapd; kUj;Jt hPjpahd Fwpg;g[fis tUk; fhyj;jpYk; 
cgnahfg;gLj;jpf; bfhs;st[k; KG kdJld; rk;kjpf;fpnwd;. 
 
Ma;t[f;Fl;gLgthpd; bgah;/ Kfthp  : 
    ifbahg;gk;  : 
     njjp  : 
 
Ma;thshpd; bjhiyngrp vz;  9597484444 
 
 kdpj bewpKiwf; FG mYtyfj;jpd; bjhiyngrp vz;. 0422-2570170  Extn. 5818 
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PSG Institute of Medical Science and Research, Coimbatore 
 
INFORMED CONSENT 
 
 
I , AKILA.K ,  am  carrying out a study on the topic: PATCH TESTING TO 
DETECT CONTACT HYPERSENSITIVITY TO TOPICAL 
CORTICOSTEROIDS 
 
 as part of my research project being carried out under the aegis of the Department 
of: DERMATOLOGY VENEROLOGY & LEPROLOGY   
 
 My  research guide is: Dr. C.R.SRINIVAS. 
 
The justification for this study is:  
 
  Topical steroids are the most important therapy used in allergic contact dermatitis 
(ACD),atopic dermatitis,stasis dermatitis etc.,. But contact sensitivity from steroids 
themselves is becoming increasingly reported in the past decade. It should be 
suspected, especially, if there is no response to steroid therapy or worsening in the 
pre-existing lesions. Knowledge of allergen will enable the patient to receive 
appropriate treatment which will improve their dermatitis. Diagnosis is best done 
by patch testing which is read on 48hrs, 5th and 7th day 
 
 
The objectives of this study are:  
 
Primary Objective:  
 
 To study the contact hypersensitivity of patients to topical steroids who do not 
respond to topical corticosteroids in allergic contact dermatitis patients. 
 
 
 
Secondary Objective:   
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To find the prevalence of contact hypersensitivity to topical corticosteroids in 
allergic contact dermatitis patients attending our OPD and provide a allergen free 
alternative medicament 
 
 
Study participants: Patients with  
All patients attending our dermatology out- patient department-males/females, with 
history of topical steroid application, who do not respond to /or aggravate with topical 
corticosteroids. 
 
Location:  PSGIMS & R 
We request you to kindly cooperate with us in this study. We propose to collect 
background information and other relevant details related to this study. We will be 
carrying out:  
 
Initial interview (specify approximate duration): 15 minutes.  
 
Data collected will be stored for a period of 10 years. We will not use the data as 
part of another study. 
 
Clinical examination will be done to assess if any active lesions are present in the 
body. 
 
Procedure: 
Patch test will be done on the upper back using Finn Chambers with the cosmetic 
series .Grading is according to International Contact Dermatitis Research 
Group(ICDRG) scale day 3 , day 5 and day7.The patch test area should not be 
washed until day 3,should not be exposed to sunlight. 
 
Benefits from this study:   Knowledge of allergen will enable to find the suitable 
topical corticosteroid preparations devoid of the allergen which will improve their 
dermatitis. 
 
Risks involved by participating in the study: will develop small allergic reaction 
over back which can be treated by taking antihistamines for 3days. 
 
How the results will be used:  
Based on these results patch testing is non invasive and simple procedure to detect 
contact hypersensitivity to topical corticosteroids.  
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If you are uncomfortable in answering any of our questions during the course of 
the interview / biological sample collection, you have the right to withdraw from 
the interview / study at anytime. You have the freedom to withdraw from the 
study at any point of time. Kindly be assured that your refusal to participate or 
withdrawal at any stage, if you so decide, will not result in any form of 
compromise or discrimination in the services offered nor would it attract any 
penalty. You will continue to have access to the regular services offered to a 
patient. You will NOT be paid any remuneration for the time you spend with us 
for this interview / study. The information provided by you will be kept in strict 
confidence. Under no circumstances shall we reveal the identity of the respondent 
or their families to anyone. The information that we collect shall be used for 
approved research purposes only. You will be informed about any significant new 
findings - including adverse events, if any, – whether directly related to you or to 
other participants of this study, developed during the course of this research which 
may relate to your willingness to continue participation. 
 
Consent: The above information regarding the study, has been read by me/ read to 
me, and has been explained to me by the investigator. Having understood the same, 
I hereby give my consent to them to interview me. I am affixing my signature / left 
thumb impression to indicate my consent and willingness to participate in this 
study (i.e., willingly abide by the project requirements).  
 
Signature / Left thumb impression of the Study Volunteer / Legal Representative:  
 
 
 
Signature of the PI with date:      Witness: 
 
Contact number of PI: 9597484444 
 
Contact number of Ethics Committee Office:  0422 2570170 Extn.: 5818 
 
PATIENT INFORMATION SHEET: 
1. Demographics   
2. Complaints with duration  
3. Seasonal variation  H/o atopy 
4. Site involved   
5. Erythema/Vesicles/Oozing/Pustules/Scaling/Depigmentation/Purpura/ 
Lichenification 
6. History of any other skin disorder  
7. History of systemic illness 
8. History of treatment for the skin lesions with duration- topical or systemic - 
steroids, antibiotics, antifungal, others. If so details of the same – name and brand  
9. How long did he/she use the topical steroids? 
10. Was he/she applying it regularly or irregularly? 
11. If irregular how many days he/she did not apply  
12. Is he/she on oral steroids or other immunosuppressants? 
13. Probable diagnosis: 
 
CORTICOSTEROID SERIES 
S.NO  ANTIGEN  %  DAY  
3  5  7  
01  Control              
02  Budesonide  0.01          
03  Betamethasone-17-valerate  1           
04  Triamcinolone acetonide 1           
05  Tixocortol-21-pivalate  0.1           
06  Aclolometasone-17,21-dipropionate  1           
07  Clobetasole 17 propionate  1           
08  Dexamethazone-21-phosphate disodium 
salt  
1           
09  Hydrocortisone-17-butyrate  1           
 
PATIENTS OWN: 
